| Literature DB >> 35791321 |
S P Gatyeni1, C W Chukwu1, F Chirove1, F Nyabadza1.
Abstract
SARS-CoV-2 (COVID-19) belongs to the beta-coronavirus family, which include: the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV). Since its outbreak in South Africa in March 2020, it has lead to high mortality and thousands of people contracting the virus. Mathematical analysis of a model without controls was done and the basic reproduction number ( R 0 ) of the COVID-19 for the South African pandemic determined. Permissible controls were introduced and an optimal control problem using the Pontraygain Maximum Principle is formulated. Numerical findings suggest that joint implementation of effective mask usage, physical distancing and active screening and testing, are effective measures to curtail the spread of the disease in the human population. The results obtained in this paper are of public health importance in the control and management of the spread for the novel coronavirus, SARS-CoV-2, in South Africa.Entities:
Keywords: COVID-19; Constant control; Model fitting; Numerical simulations; Optimal control measures; South Africa
Year: 2022 PMID: 35791321 PMCID: PMC9245336 DOI: 10.1016/j.sciaf.2022.e01268
Source DB: PubMed Journal: Sci Afr ISSN: 2468-2276
Basic features of South African COVID-19 Data.
| Statistics | Infected | Recoveries | Deaths |
|---|---|---|---|
| Minimum | 927.00 | 0.00 | 1.00 |
| Maximum | 364328.00 | 191059.00 | 5033.00 |
| 4290.50 | 1473.00 | 82.50 | |
| Median | 21343.00 | 10104.00 | 407.00 |
| 94991.50 | 50967.00 | 1903.50 | |
| Mean | 68278.77 | 34040.64 | 1152.82 |
| Range | 363401.00 | 191059.00 | 5032.00 |
| Standard Deviation | 94256.84 | 47407.55 | 1422.69 |
| Skewness | 1.63 | 1.67 | 1.25 |
| Kurtosis | 1.69 | 2.05 | 0.40 |
Fig. 1Plots representing EDA of the COVID-19 in South Africa for: (a) Daily infected cases. (b) Daily recovered class. (c) Daily deaths cases.
Fig. 2Model flow chart depicting the dynamics of COVID-19 transmissions.
Fig. 3Model fit to data for COVID-19 early growth of new cases in South Africa for the first wave from 26 March to 19 July 2020. Optimal parameter values:
Fig. 4PRCC plots showing the effects of the dynamics of parameter values on COVID-19 daily new cases in South Africa for (a) parameters and on (b) parameters and on
Fig. 5Contour plot of as a function of versus
Parameters of (COVID-19) model for South Africa and their values.
| Symbol | Parameter description | Value [Range] day | Source |
|---|---|---|---|
| Recruitment rate | 11244 [10000 - 25000] | Estimated in | |
| Mortality rate | 0.0091 [0.0050 - 0.010] | ||
| Rate of active testing | 0.2070 [0.4000 - 1.000] | Data fit | |
| Diagnosed induced death rate | 0.1500 [0.0000 - 0.100] | ||
| Un-diagnosed induced death rate | 0.0089 [0.0000 - 0.100] | Data fit | |
| Modification parameter | 0.5663 [0.0000 - 1.000] | Data fit | |
| Rate at which exposed become infectious | 0.5732 [0.2000 - 0.600] | Data fit | |
| Proportion of | 0.9799 [0.0000 - 1.000] | By definition | |
| Recovery rate of diagnosed infected humans | 0.1800 | Data fit | |
| Recovery rate of undiagnosed infected humans | 0.0206 [0.0000 - 0.100] | ||
| Infection rate | 1.3295 [1.2100 - 1.500] | Data fit | |
| Mask usage and physical distancing | 0.7557 [0.0000 - 1.000] | Data fit | |
| Active screening and testing | 0.3728 [0.0000 - 1.000] | Data fit |
Costs associated with optimal control variables used for simulations.
| Symbol | Parameter description | Base line Values (day | Source |
|---|---|---|---|
| Weight associated with reducing the undiagnosed infected human | 1 | Estimated | |
| Weight on the cost of the prevention | 0.9 | Estimated | |
| Weight on the cost of the active screening and testing | 0.5 | Estimated |
Fig. 6The dynamics on COVID-19 using control with for (a) undiagnosed humans (b) the control profile for
Fig. 7The dynamics on COVID-19 using control , with for (a) undiagnosed humans (b) the control profile for
Fig. 8The dynamics on COVID-19 using controls and for (a) undiagnosed humans (b) the control profile for and